 |
年間契約型資訊服務
商品編碼
1524359
肝細胞癌：KOL 見解Hepatocellular Carcinoma - KOL Insight |
||||||
價格
簡介目錄
本報告分析了肝細胞癌（HCC）治療環境的進展狀況。領先的KOL就Roche Tecentriq（atezolizumab）和 Avastin（(bevacizumab）的整合作為不可切除 HCC 的一線治療提供了見解，此外，AstraZeneca的Imfinzi（durvalumab）和Imjudo（tremelimumab）對於有使用Avastin禁忌的患者的使用增加，以及Bristol Myers Squibb的Opdivo（nivolumab）聯合Uervoy（ipilimumab）作為一線治療的潛力。了解新療法的新興作用以及對臨床實踐和藥物開發的影響。
本報告回答的關鍵問題：
- KOL 使用Roche Tecentriq（atezolizumab）和Avastin（(bevacizumab）聯合療法治療肝細胞癌效果如何？自IMbrave050資料以來，KOL在輔助設定中是否使用過這種組合？
- 專家認為Tecentriq和Avastin合併治療取得進展後或不適合合併治療的患者較適合使用哪種藥物？
- AstraZeneca的 Imfinzi（durvalumab）和 Imjudo（tremelimumab）核准後的使用情況如何？如何將 KOL 納入治療演算法？
- KOL 如何使用 TKI Nexavar（sorafenib；Bayer）和 Lenvimalenvatinib；Eisai/Merck KGaA）以及如何在治療演算法中定位？
- KOL 對 Stivarga（regorafenib；Bayer）、Cabometyx（cabozantinib；Exelixis/Ipsen）、Cyramza（ramucirumab；Eli Lilly）和 HCC 等藥物的相對地位有何看法？
- KOL 認為哪些管線處理方法最有前景？
- 未來五年，什麼會為肝細胞癌治療典範帶來最大的改變？
本報告調查的主要品牌
|
|
調查目標公司
|
|
目錄
執行摘要
目前/未來的治療演算法
研究目的
檢查點抑制劑
- 核准的藥物
- Tecentriq（atezolizumab；Roche）、Avastin（bevacizumab；Roche）
- Imfinzi（durvalumab；AstraZeneca）、Imjudo（tremelimumab；AstraZeneca）
- Opdivo（nivolumab；BMS/Ono Pharmaceutical）、Yervoy（ipilimumab；BMS）
- Keytruda（pembrolizumab；Merck KGaA）
- 研究藥物
- Tevimbra/Tizveni (tislelizumab; BeiGene)
- Camrelizumab and rivoceranib (Jiangsu Hengrui Medicine/Elevar Therapeutics)
- Nofazinlimab (CStone Pharmaceuticals/3SBio) and Loqtorzi (toripalimab; Coherus BioSciences/Junshi Biosciences)
酪胺酸激酶抑制劑
- 核准的藥物
- Nexavar（sorafenib；Bayer）
- Lenvima（lenvatinib；Eisai/Merck KGaA）
- Cabometyx（cabozantinib；Exelixis/Ipsen）
- Stivarga（regorafenib；Bayer）
VEGFR抑制劑
- 核准的藥物
- Cyramza（ramucirumab；Lilly）
其他作用機轉
- 研究藥物
- Namodenoson（Can-Fite BioPharma）
- Tilagolumab（Roche）
- Rivmoniplimab、budigalimab（AbbVie）
- Kasdozokitug（Coherus BioSciences）
- Fostrox（fostroxacitabine brapamide；Medivir）
- Amezalpat（TPST-1120；Tempest Therapeutics）
未來治療趨勢
- 主要考慮因素：摘要
附錄
- KOL 詳細信息
- 美國的 KOL
- 歐洲的 KOL
簡介目錄
Explore the evolving landscape of hepatocellular carcinoma (HCC) treatment. Leading KOLs provide insights on the consolidation of Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) as the first-line treatment for unresectable HCC, the rising use of AstraZeneca's Imfinzi (durvalumab) plus Imjudo (tremelimumab) for patients contraindicated for Avastin, and the potential of Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment. Gain an understanding of the emerging role of novel therapies and the implications for clinical practice and drug development.
Key questions answered:
- How do KOLs use Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) in HCC? Have KOLs used the combination in the adjuvant setting since the data from IMbrave050?
- Which agents do the experts prefer to use after Tecentriq plus Avastin progression or in patients unsuitable for the combination?
- What has the uptake of AstraZeneca's Imfinzi (durvalumab) and Imjudo (tremelimumab) been like since its approval? How do KOLs place it in the treatment algorithm?
- How do KOLs use TKIs Nexavar (sorafenib; Bayer) and Lenvima (lenvatinib; Eisai/Merck & Co.), and how are they placed in the treatment algorithm?
- What do KOLs think of agents such as Stivarga (regorafenib; Bayer), Cabometyx (cabozantinib; Exelixis/Ipsen) and Cyramza (ramucirumab; Eli Lilly) and their relative positioning for HCC?
- Which pipeline therapies do KOLs find the most promising and why?
- What will be the most significant changes to the HCC treatment paradigm over the next five years?
Key brands covered in this report:
|
|
Companies:
|
|
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
Checkpoint inhibitors
- Approved drugs
- Tecentriq (atezolizumab; Roche) and Avastin (bevacizumab; Roche)
- Imfinzi (durvalumab; AstraZeneca) and Imjudo (tremelimumab; AstraZeneca)
- Opdivo (nivolumab; BMS/Ono Pharmaceutical) and Yervoy (ipilimumab; BMS)
- Keytruda (pembrolizumab; Merck & Co.)
- Pipeline drugs
- Tevimbra/Tizveni (tislelizumab; BeiGene)
- Camrelizumab and rivoceranib (Jiangsu Hengrui Medicine/Elevar Therapeutics)
- Nofazinlimab (CStone Pharmaceuticals/3SBio) and Loqtorzi (toripalimab; Coherus BioSciences/Junshi Biosciences)
Tyrosine kinase inhibitors
- Approved drugs
- Nexavar (sorafenib; Bayer)
- Lenvima (lenvatinib; Eisai/Merck & Co.)
- Cabometyx (cabozantinib; Exelixis/Ipsen)
- Stivarga (regorafenib; Bayer)
VEGFR inhibitors
- Approved drugs
- Cyramza (ramucirumab; Lilly)
Other mechanisms of action
- Pipeline drugs
- Namodenoson (Can-Fite BioPharma)
- Tiragolumab (Roche)
- Livmoniplimab and budigalimab (AbbVie)
- Casdozokitug (Coherus BioSciences)
- Fostrox (fostroxacitabine bralpamide; Medivir)
- Amezalpat (TPST-1120; Tempest Therapeutics)
Future treatment trends
- Key insights summary
Appendix
- KOL details
- KOLs from the USA
- KOLs from Europe
02-2729-4219
+886-2-2729-4219
